Peptides below roughly 1000 Da absorb relatively well nasally
Six-month follow-up labs are standard
Cons: Less dosing flexibility, higher cost
Results showed combination therapy achieved 83% clinical response versus 61% for golimumab monotherapy and 75% for guselkumab monotherapy, with AEs including UC flares, respiratory infections, and headache but no deaths or malignancies during the 12-week induction period, demonstrating superior efficacy of dual biologic approach over single-agent treatment ( An ongoing Phase 2b randomized, double-blind trial investigates the golimumab/guselkumab combination therapy (DUET-UC Study, NCT05242484) at various dose levels compared to placebo and individual monotherapies in 577 patients with moderately to severely active UC who failed prior advanced therapies
Submission for the use of the drug to treat type 2 diabetes is expected next year.
Discuss Your Medical History : Share details of your complete medical history, including any other medications you take, previous side effects from other drugs, and any family history of conditions that might impact the safety of semaglutide, like thyroid or pancreatic issues
.webp)
